Article thumbnail

Objective markers of drug effects on brain function from recordings of scalp potential in healthy volunteers

By Peter H. Boeijinga

Abstract

In order to stress the importance of P300 responses in drug development, we describe the spatiotemporal characteristics of this objective, evoked event-related potential. These brain activations reflect mnemonic function, in which limbic structures play a role. It is demonstrated that a pharmacological challenge concerning, for example, the cholinergic system in young healthy volunteers induces modifications in P300 reminiscent of the aging brain. We use this type of observation to build a model in which it can be verified whether the deterioration can be counteracted by treatment with “cognition-enhancing” drugs. If we accept the extrapolation of the pharmacological effects to symptomatology, scalp potential analysis offers an appropriate tool for the study of drug interactions in early proof-of-concept models

Topics: Clinical Research
Publisher: Les Laboratoires Servier
OAI identifier: oai:pubmedcentral.nih.gov:3181706
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects.
  2. (1998). An MEG analysis of the P300 in visual discrimination tasks. Electroencephalogr Clin Neurophysiol.
  3. (1997). An overview of age-related changes in the scalp distribution of P3b. Electroencephalogr Clin Neurophysiol.
  4. Central cholinergic systems and the P3 evoked potential.
  5. (1995). Cognitive brain potentials and regional cerebral blood flow equivalents during two- and three-sound auditory “oddball tasks.” Electroencephalogr Clin Neurophysiol.
  6. Cognitive psychophysiology in nootropic drug research: effects of Ginkgo biloba on event-related potentials (P300) in age-associated memory impairment.
  7. Combined eventrelated fMRI and EEG evidence for temporal-parietal cortex activation during target detection.
  8. (1996). Comparison of late components in simultaneously recorded event-related electrical potentials and event-related magnetic fields. Electroencephalogr Clin Neurophysiol.
  9. (1998). Cortical-hippocampal auditory processing identified by magnetoencephalography.
  10. (1992). Diazepam effects on the P3 eventrelated potential. J Clin Psychopharmacol.
  11. (1997). Differential outcome from magneto- and electroencephalography for the analysis of human cognition.
  12. (1998). Differentiating the effects of centrally acting drugs on arousal and memory: an event-related potential study of scopolamine, lorazepam and diphenhydramine.
  13. EEG and auditory evoked potential P300 compared with psychometric tests in assessing vigilance after benzodiazepine sedation and antagonism.
  14. (1997). EEG and ERP assessment of normal aging. Electroencephalogr Clin Neurophysiol.
  15. (1998). Effects of physostigmine in quantitative electroencephalogram and cognitive performance. Hum Psychopharmacol.
  16. Effects of rivastigmine on lorazepam-induced changes in EEG: a double-blind placebo-controlled study. Methods and findings. Exp Clin Pharmacol. 2002;24(suppl D):155. O-
  17. Effects of serotoninselective and classical antidepressants on the auditory P300 cognitive potential.
  18. Electrophysiological differences between subtypes of dementia.
  19. Event-related potentials and psychopharmacology. Cholinergic modulation of P300.
  20. Eventrelated potentials and visual spatial attention: influence of a cholinergic drug.
  21. (1989). Further observations on the effects of subhypnotic doses of midazolam in normal volunteers. Psychopharmacol Bull.
  22. (1998). Generators of the late potentials in auditory and visual oddball tasks. Electroencephalogr Clin Neurophysiol.
  23. Infrequent events transiently activate human prefrontal and parietal cortex as measured by functional MRI.
  24. Neurochemical substrates and neuroanatomical generators of the event-related P300.
  25. (1998). Neuromagnetic activity in the human left cerebral hemisphere concerning logical processing during auditory oddball stimulation.
  26. (1990). P300 assessment of early Alzheimer’s disease. Electroencephalogr Clin Neurophysiol.
  27. Prefrontal activation evoked by infrequent target and novel stimuli in a visual target detection task: an event-related functional magnetic resonance imaging study.
  28. Psychometrics and event-related potentials in the diagnosis of dementia.
  29. randomized, placebo-controlled study of the effects on wake-EEG of 2 doses of Praxilene ® using a cross-over design in elderly healthy male volunteers. Eur Neuropsychopharmacology. 2000;10(suppl 3):S363.
  30. (1994). Statistical decision tree: a tool for studying pharmaco-EEG effects of CNS-active drugs.
  31. (1995). Synergistic anticholinergic and antiserotoninergic effects in humans.
  32. (1987). The distinction between different types of dementia using evoked potentials. Electroencephalogr Clin Neurophysiol Suppl.
  33. (1991). The effect of tetrahydroaminoacride (THA) on P300 in Alzheimer’s disease. Biol Psychiatry.
  34. (1996). The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills.
  35. (1999). The functional neuroanatomy of novelty processing: integrating ERP and fMRI results. Cereb Cortex.
  36. (1999). The functional neuroanatomy of target detection: an fMRI study of visual and auditory oddball tasks. Cereb Cortex.
  37. (1988). The relation between lorazepam-induced auditory amnesia and auditory evoked potentials. Anesth Analg.